转甲状腺素蛋白淀粉样变心肌病的研究现状  

Research Status in Transthyretin Amyloid Cardiomyopathy

作　　者：李帅奇 凌智瑜[1] 

机构地区：[1]重庆医科大学附属第二医院心血管内科,重庆

出　　处：《临床医学进展》2024年第1期476-487,共12页Advances in Clinical Medicine

摘　　要：转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)是一种罕见的进行性衰弱性疾病。ATTR-CM主要是由于TTR淀粉样蛋白在心肌中的积聚而引起的。然而,ATTR-CM的临床表现多样且缺乏特异性,因此很容易被误诊或漏诊。目前有多种辅助检查可用于更准确地诊断该病,但它们的临床价值各不相同。尽管该病的整体预后不佳,但随着对该病的深入研究,越来越多的治疗方案正在被探索并进行临床实验。本文对转甲状腺素蛋白淀粉样变心肌病的研究现状进行了综述。Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive and debilitating disease. ATTR-CM is mainly caused by the accumulation of TTR amyloid protein in the myocardium. Howev-er, the clinical manifestations of ATTR-CM are diverse and lack specificity, so it is easily misdiag-nosed or missed. There are a variety of tests available to more accurately diagnose the disease, but their clinical value varies. Despite the overall poor prognosis of the disease, more and more treat-ment options are being explored and undergoing clinical trials as the disease is further studied. This article reviews the research status in transthyretin amyloid cardiomyopathy.

关 键 词：转甲状腺素蛋白淀粉样变心肌病 临床表现 诊断价值 病因治疗 

分 类 号：R54[医药卫生—心血管疾病]